MROH2B and early-onset autosomal dominant Alzheimer disease: The potential of sPIF therapy for Alzheimer’s Disease was previously reported14 and sPIF’s ability to reduce neuronal loss and microglial activation in a murine model of perinatal brain injury provides further evidence of sPIF’s putative neuroprotective properties7,15.